Navigation Links
KaloBios Provides Clinical Update and Reports Second Quarter Financial Results
Date:8/7/2014

ollaboration agreement with Sanofi Pasteur. KaloBios has stated that it intends to seek a partner with a focus on infectious disease, hospital pharmaceuticals, or cystic fibrosis who can accelerate and financially support the future development of KB001-A."We are very excited about the recent progress we have made on our programs," said Nestor A. Molfino, MD, MSc, Chief Medical Officer of KaloBios. "Completing enrollment in our Phase 2 KB001-A study in CF patients in a timeframe that will potentially allow us to report out top-line data in early 2015 was a major achievement for the company. At the same time, completing enrollment in the KB004 Phase 1 dose escalation study sets the stage for us to initiate enrollment in the high-dose cohorts in the Phase 2 efficacy-seeking portion of our KB004 study in the second half of 2014."

Key Anticipated Milestones for 2014-20152H 2014:Full enrollment of the KB001-A CF Phase 2 study (completed in July 2014)Q4 2014:

Completion of enrollment in at least one indication in the Phase 2 expansion portion of our KB004 study in hematologic malignanciesQ1 2015:

Top line KB001-A CF Phase 2 study resultsSecond Quarter 2014 Financial Results
Net loss for the three months ended June 30, 2014 was $9.8 million or $0.30 per common share, as compared to $11.8 million or $0.49 per common share for the same period in 2013. 

No contract revenue was reported for the second quarter of 2014 as compared to $15,000 reported in the same period in 2013. The decrease in contract revenues was due to the completion of all substantive performance obligations related to research support activities under our agreement with Sanofi Pasteur.

Research and development (R&D) expenses were $6.7 million for the three months ended June 30, 2014 as compared to $9.6 million for the same period in 2013. The decrease in R&D expense was primarily due to decreased clinical trial activity compared with the prior period
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. KaloBios Provides Update on KB001-A Partnership and Clinical Status
2. KaloBios Appoints Harry Lam, Ph.D. as Head of Manufacturing
3. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
4. KaloBios Elects Laurie Smaldone Alsup, M.D. to Board
5. KaloBios to Present at Leerink Swann Rare Disease Roundtable
6. KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
7. Herb C. Cross to Join KaloBios as Chief Financial Officer
8. KaloBios KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
9. KaloBios to Present at Stifel Healthcare Conference 2013
10. KaloBios Reports First Quarter 2013 Financial Results
11. KaloBios to Present at Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 ... stage. Growing ageing population and rise in the incidence ... of chronic wounds and in affordability of better quality ... Chinese wound care market. Universal coverage of public health ... products would further stimulate demand. Based on the findings ...
(Date:9/30/2014)... , Sept. 30, 2014 BioStructures, LLC ... American Association of Tissue Banks (AATB), it was ... Executive Officer. Accreditation follows an intensive ... specially trained AATB inspector.  It establishes that the ... the facility meets or exceeds the standards set ...
(Date:9/30/2014)... , Sept. 30, 2014  Proteomics is a ... a new report from Kalorama Information.  The healthcare market ... occurred in proteomics in the past two years.  ... agreements between private proteomic companies and academic institutions, ... novel proteomics innovator companies.  Kalorama observed the industry ...
Breaking Medicine Technology:China Wound Care Market 2China Wound Care Market 3Biostructures, LLC Earns AATB Accreditation 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3
(Date:9/30/2014)... Maryland-led research team has been awarded a three-year ... Health (NIH) to develop new imaging technologies and ... of how large networks of neurons in the ... will help researchers identify the precise interactions between ... decision-making and speaking, and alterations in these interactions ...
(Date:9/30/2014)... Charlotte, N.C. (PRWEB) September 30, 2014 ... as an option to help diabetics curb their sweet ... journal Nature this September, suggests that zero-calorie ... for type 2 diabetes. , The Weizmann Institute ... when they fed artificial sweeteners to mice, the mice ...
(Date:9/30/2014)... FL (PRWEB) September 30, 2014 Regenerative ... to two new clinics in Nashville, Tennessee. RMS welcomes ... Apnea Institute, and the expansion of a new treatment ... introduction of the Sleep Apnea Institute to Nashville, the ... suffer from sleep apnea: both diagnosed and undiagnosed. With ...
(Date:9/30/2014)... -- Medicare should cover low-dose computed tomography lung cancer ... a coalition of more than 60 patient and medical ... Cancer Alliance, the Society of Thoracic Surgeons, the American ... American Society of Clinical Oncology, made its point in ... Medicare & Medicaid Services (CMS). Such screening reduces ...
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 Healthcare ... at the National Association of Health Advocacy Consultants (#NAHAC) ... Healthcare Advocacyā€¯ (#NAHAC14) to be held October 30th - ... its debut at NAHAC14: Standards and Best Practices for ... grows into a profession, advocates have needed a set ...
Breaking Medicine News(10 mins):Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... ... tidbits people are learning about their ancestors is not just trivia. This information is highly ... understanding their familial and ancestral past. , ... Doylestown, PA (PRWEB) March 13, 2010 -- Noted author Donna Evans Strauss ...
... (Nasdaq: SIAL ) today announced that it has entered into an agreement with Pfizer under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small ... ... , , ... ...
... 19 year olds and to those currently not in employment in a bid to increase awareness of safety at work. , ... , , ... ... ...
... 15, 2010 The Autism Consortium, an innovative research, ... enhancing clinical care for families with autism spectrum disorders ... study of genetic testing methods for autism spectrum disorders ... early online release in their eFirst pages today and ...
... AllegroMedical.com, ... meaning that just under 13 years, it has served more than a million customers nationwide. ... (Vocus) March 14, 2010 ... website launched in 1997. The first company to sell medical supplies online, it has grown ...
... its kind to date using cardiac computed tomography angiography, ... coronary artery disease are at higher risk of developing ... Henry Ford Hospital researchers say. Researchers analyzed the ... computed tomography angiography and found that those with a ...
Cached Medicine News:Health News:Author Proves What Celebrities are Learning in "Who Do You Think You Are?" is More Important Than They Realize 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 3Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 4Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 5Health News:British Safety Council Offers Free Health and Safety Qualifications 2Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 2Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 3Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 4Health News:Online Medical Supplies Superstore Ships 1 Millionth Order 2Health News:Family history is strong predictor of obstructive coronary artery disease using CCTA 2
... line of Personal Catheters® ... you would choose for ... configurations - standard, antibacterial, ... - are based on ...
... It's easy on delicate ... design and hydrophilic coating provide ... lubricating gel. It's easy to ... the catheter with its own ...
... line of Personal Catheters® ... you would choose for ... configurations - standard, antibacterial, ... - are based on ...
... Medical's line of Personal ... catheters you would choose ... product configurations - standard, ... hydro - are based ...
Medicine Products: